文献速递主动脉疾病外周动脉疾病

CERAB技术治疗主髂动脉闭塞性疾病的英国多中心研究结果

Treatment of Aortoiliac Occlusive Disease With the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) Technique: Results of a UK Multicenter Study.
PubMed 文献 · J Endovasc Ther · 2021-06-23

这项英国多中心回顾性研究分析了116例接受覆膜支架主髂动脉分叉重建(CERAB)的主髂动脉闭塞性疾病(AIOD)患者,其中48%表现为慢性肢体威胁性缺血(CLTI),82%为TASC D级病变。中位随访18个月,1年免于靶病变再干预率为94%,1年一期、辅助一期和二期通畅率分别为88%、94%和98%。研究表明CERAB是严重AIOD病变的有效血运重建选择。

要点

  • CERAB术后1年一期通畅率88%,二期通畅率98%,围手术期和中期结果可接受。
  • TASC D级病变、严重主动脉钙化和基线组织缺损与靶病变再干预风险增加相关。
  • CERAB可作为严重主髂动脉闭塞性疾病的血运重建选择,值得与开放手术进行随机对照比较。

核心结论

  • 在严重AIOD病变的实用队列中,CERAB的围手术期(<30天)和中期并发症率、死亡率和通畅率表明其是有效的血运重建选择。
  • 有必要开展随机对照试验将CERAB与AIOD的外科治疗进行直接比较。

研究设计与样本

  • 英国6中心回顾性病例分析,纳入2012年11月1日至2020年3月31日接受CERAB的患者。
  • 共116例患者,中位年龄65岁(范围42-90岁),76%为男性。
  • 48%表现为CLTI(Rutherford 4-6级),52%表现为间歇性跛行(Rutherford 1-3级)。
  • 82%为TASC D级AIOD病变;90%患者存在严重主动脉钙化,80%存在严重髂动脉钙化。
  • 中位随访18个月(范围1-91个月),2例(1.7%)失访。

主要发现

  • 5例(4.3%)死亡,2例(1.7%)接受大截肢。
  • 14例(12.1%)需要血管内靶病变再干预(TLR),4例(3.4%)需要外科TLR。
  • 7例(6%)发生主动脉/髂动脉支架闭塞。
  • Kaplan-Meier 1年免于TLR率为94%,1年一期、辅助一期和二期通畅率分别为88%、94%和98%。
  • 亚组分析显示需要TLR的相关因素包括:TASC D级病变(OR=2.45,95%CI 1.44-3.71)、严重主动脉钙化(OR=2.01,95%CI 1.03-2.20)、基线存在组织缺损(OR=1.43,95%CI 1.01-4.63)。

临床怎么用

  • 对于严重AIOD病变(尤其是TASC D级),CERAB可作为血运重建的有效选择。
  • 术前应评估主动脉钙化程度和是否存在组织缺损,以识别TLR高风险患者。

局限性

  • 回顾性研究设计。
  • 中位随访时间仅18个月,缺乏长期结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This UK multicenter study aims to report early- and medium-term results following covered endovascular reconstruction of aortic bifurcation (CERAB) for the treatment of aortoiliac occlusive disease (AIOD) in patients with chronic limb threatening ischemia (CLTI) or intermittent claudication (IC). MATERIALS AND METHODS: Retrospective case analysis was performed of patients who underwent CERAB between November 1, 2012 and March 31, 2020 in 6 centers across the United Kingdom. Anatomical data, including degree of plaque calcification, were assessed using preoperative imaging. Outcome measures included mortality, perioperative complications, target lesion reintervention (TLR), and major limb amputation. Primary, assisted primary, and secondary patencies were calculated at set intervals. RESULTS: A total of 116 patients underwent CERAB over the study period for the following reasons [48% presenting with CLTI (Rutherford 4-6) and 52% with IC (Rutherford 1-3)]; 82% presented had Trans-Atlantic Inter-Society Consensus (TASC) D AIOD disease. Median age was 65 years (range 42-90 years); 76% of the cohort were male. Severely calcified aortic and iliac lesions were noted in 90% and 80% of patients, respectively. Over a median follow-up of 18 months (range 1-91 months), 2 (1.7%) patients were lost to follow up. In total 5, (4.3%) patients died and 2 (1.7%) had a major amputation. Endovascular TLR was required in 14 (12.1%) patients at last follow up. Surgical TLR was performed in 4 (3.4%) patients at last follow-up. Seven (6%) patients developed an aortic/iliac stent occlusion at last follow-up. The Kaplan-Meier (KM) freedom from TLR at 1 year was 94% and KM 1-year primary patency, assisted primary patency, and secondary patency were 88%, 94%, and 98% respectively. Subanalysis found the following features were associated with need for TLR; TASC D disease (OR = 2.45, 95% CI 1.44 to 3.71), severe aortic calcification (OR = 2.01, 95% CI 1.03 to 2.20), and presence of tissue loss at baseline (OR = 1.43, 95% CI 1.01 to 4.63). CONCLUSION: Perioperative (<30 days) and medium-term morbidity, mortality, and patency rates in this pragmatic cohort of patients with severe AIOD lesions show that CERAB is a valid revascularization option. A direct comparison with surgical treatments for AIOD in a randomized controlled trial is justified.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Saratzis A, Salem M, Sabbagh C, et al. Treatment of Aortoiliac Occlusive Disease With the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) Technique: Results of a UK Multicenter Study. J Endovasc Ther. 2021. PMID: 34160321. doi:10.1177/15266028211025028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。